Beyond the Deal Volume: A Conversation With CEO Doug Drew of USOSM
Driven by a highly fragmented market landscape and sustained patient demand for care, the dental industry has emerged as an appealing sector for strategic consolidation and acquisition opportunities in the past five years. According to data captured in the LevinPro HC M&A database, the dental industry represents 48% of the Physician Medical Group sector’s activity, with 219 transactions announced since the start of 2025. Formed in 2017 and backed by Oak Hill Capital Partners, U.S. Oral Surgery Management (USOSM) has crafted a reputation as a dominating force in the dental space. With a presence in more than 30 states, USOSM provides operational, financial and administrative support... Read More »
October Deal Volume Dips 17% as Market Pressures Mount
The last few months have been a relentless storm of reimbursement and market changes. Far from finding calm, October has seen new challenges that have that power to impact healthcare M&A and deal activity. With substantial economic and regulatory pressures, healthcare M&A activity in October declined, but remained steady overall. According to data captured in the LevinPro HC database on November 3, preliminary numbers indicate that there was a 17% drop in deal volume from September (195 transactions) to October 2025 (162 transactions). It is worth noting that September 2025’s high deal activity is more of an outlier; October’s activity was more consistent with the... Read More »
AI, Pharma Services and Tariffs: The Healthcare Outlook from HPE New York
In mid-October, McDermott Will & Schulte’s Healthcare Private Equity New York conference brought healthcare leaders together to analyze the key challenges and trends shaping the industry in 2025. For one busy day, attendees heard from a series of panels that guided them through the complexities of private equity in healthcare and highlighted the most compelling investment sectors. It should be noted that media at the conference were bound by the Chatham House Rule, so we will refer to panelists anonymously unless we have received direct permission to use their names. “The boom days are back,” one panelist declared, echoing the enthusiasm at the conference around the... Read More »
Inside the 2025 Clinical Trials M&A Market
The clinical trials market, part of our newly formed Life Sciences R&D sector, has seen a shift in M&A deal volume over the last few years. The post-pandemic dealmaking frenzy has cooled, with acquirers now making more strategic and deliberate moves over the large-scale expansion of previous years. According to data captured in the LevinPro HC database, deal volume was modest before the post-pandemic surge, with 12 deals in 2019, 14 in 2020 and 18 in 2021. Volume escalated more than 66% in 2022 when 30 deals were reported. It hit a high in 2023 when 43 acquisitions were announced. However, M&A activity fell 37% in 2024 with 27 deals. If activity continues at its current pace,... Read More »
Private Equity Interest Drops in First Half of 2025
In the first half of 2025, private equity firms and their sponsored companies (“PE Buyers,” collectively) announced 326 transactions in the healthcare M&A market, or approximately 32% of all the 1,036 announced healthcare deals, according to data captured in the LevinPro HC platform. The deal volume in Q2:25 (148 deals) represents a nearly 17% decrease in M&A volume from Q1:25 (178 deals). Activity in Q2:25 is also 24% lower than the 194 PE-backed transactions reported in the second quarter of 2024. For the first two quarters of the year, disclosed spending reached more than $32.8 billion across 17 transactions. The first quarter saw more than $29.9 billion in disclosed spending... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
